|

BL-M14D1 Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 2

Top Sponsors

  • SystImmune Inc.1
  • Sichuan Baili Pharmaceutical Co., Ltd.1

Indications

  • Lung Cancer2
  • Cancer2
  • Poorly Differentiated and/or High Grade Neuroendocrine Neoplasms With Evidence of DLL3 Expression1
  • Metastatic or Locally Advanced Extrapulmonary Neuroendocrine Carcinoma1
  • Locally Advanced or Metastatic Large Cell Neuroendocrine Carcinoma of the Lung1

Other1 trial

A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Phase 1

Los Angeles, California1 trial

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Valkyrie Clinical Trials

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.